Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Controlled, Multicenter Study of Sacubitril/Valsartan in the Treatment of Patients With Mild to Moderate Essential Hypertension and Type 2 Diabetic Nephropathy: The Hyper-Save Study

NCT06501651 is registered in ClinicalTrials.gov with Sichuan Academy of Medical Sciences as lead sponsor.

NCT NCT06501651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06501651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Controlled, Multicenter Study of Sacubitril/Valsartan in the Treatment of Patients With Mild to Moderate Essential Hypertension and Type 2 Diabetic Nephropathy: The Hyper-Save Study
Lead sponsor
Sichuan Academy of Medical Sciences
Phase
Phase 4
Overall status
Unknown status
Start date
August 1, 2024
Completion date
April 10, 2025
Enrollment
297 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension, nephropathy, type 2 diabetes